174 related articles for article (PubMed ID: 9169736)
1. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker.
Kossaczka Z; Bystricky S; Bryla DA; Shiloach J; Robbins JB; Szu SC
Infect Immun; 1997 Jun; 65(6):2088-93. PubMed ID: 9169736
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam.
Kossaczka Z; Lin FY; Ho VA; Thuy NT; Van Bay P; Thanh TC; Khiem HB; Trach DD; Karpas A; Hunt S; Bryla DA; Schneerson R; Robbins JB; Szu SC
Infect Immun; 1999 Nov; 67(11):5806-10. PubMed ID: 10531232
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and some immunologic properties of an O-acetyl pectin [poly(1-->4)-alpha-D-GalpA]-protein conjugate as a vaccine for typhoid fever.
Szu SC; Bystricky S; Hinojosa-Ahumada M; Egan W; Robbins JB
Infect Immun; 1994 Dec; 62(12):5545-9. PubMed ID: 7960137
[TBL] [Abstract][Full Text] [Related]
4. First characterization of immunogenic conjugates of Vi negative Salmonella Typhi O-specific polysaccharides with rEPA protein for vaccine development.
Salman M; St Michael F; Ali A; Jabbar A; Cairns C; Hayes AC; Rahman M; Iqbal M; Haque A; Cox AD
J Immunol Methods; 2017 Nov; 450():27-33. PubMed ID: 28735760
[TBL] [Abstract][Full Text] [Related]
5. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.
Szu SC; Taylor DN; Trofa AC; Clements JD; Shiloach J; Sadoff JC; Bryla DA; Robbins JB
Infect Immun; 1994 Oct; 62(10):4440-4. PubMed ID: 7927707
[TBL] [Abstract][Full Text] [Related]
6. Physical and chemical characterization and immunologic properties of Salmonella enterica serovar typhi capsular polysaccharide-diphtheria toxoid conjugates.
Cui C; Carbis R; An SJ; Jang H; Czerkinsky C; Szu SC; Clemens JD
Clin Vaccine Immunol; 2010 Jan; 17(1):73-9. PubMed ID: 19889941
[TBL] [Abstract][Full Text] [Related]
7. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. Preparation, characterization, and immunogenicity in laboratory animals.
Szu SC; Stone AL; Robbins JD; Schneerson R; Robbins JB
J Exp Med; 1987 Nov; 166(5):1510-24. PubMed ID: 3681191
[TBL] [Abstract][Full Text] [Related]
8. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate.
Fattom A; Shiloach J; Bryla D; Fitzgerald D; Pastan I; Karakawa WW; Robbins JB; Schneerson R
Infect Immun; 1992 Feb; 60(2):584-9. PubMed ID: 1730492
[TBL] [Abstract][Full Text] [Related]
9. Preparation and characterization of group A meningococcal capsular polysaccharide conjugates and evaluation of their immunogenicity in mice.
Jin Z; Chu C; Robbins JB; Schneerson R
Infect Immun; 2003 Sep; 71(9):5115-20. PubMed ID: 12933854
[TBL] [Abstract][Full Text] [Related]
10. Protective efficacy and immunogenicity of Vi-porin conjugate against Salmonella typhi.
Singh M; Ganguly NK; Kumar L; Vohra H
Microbiol Immunol; 1999; 43(6):535-42. PubMed ID: 10480549
[TBL] [Abstract][Full Text] [Related]
11. S.Typhi derived OmpC peptide conjugated with Vi-polysaccharide evokes better immune response than free Vi-polysaccharide in mice.
Haque S; Sengupta S; Gupta D; Bhan MK; Kumar R; Khan A; Jailkhani B
Biologicals; 2019 Nov; 62():50-56. PubMed ID: 31606267
[TBL] [Abstract][Full Text] [Related]
12. Development of a synthetic Vi polysaccharide vaccine for typhoid fever.
Ni Y; Springer MJ; Guo J; Finger-Baker I; Wilson JP; Cobb RR; Turner D; Tizard I
Vaccine; 2017 Dec; 35(51):7121-7126. PubMed ID: 29150208
[TBL] [Abstract][Full Text] [Related]
13. Physico-chemical properties of Salmonella typhi Vi polysaccharide-diphtheria toxoid conjugate vaccines affect immunogenicity.
An SJ; Yoon YK; Kothari S; Kothari N; Kim JA; Lee E; Kim DR; Park TH; Smith GW; Carbis R
Vaccine; 2011 Oct; 29(44):7618-23. PubMed ID: 21843575
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.
Szu SC; Lin KF; Hunt S; Chu C; Thinh ND
Vaccine; 2014 May; 32(22):2618-22. PubMed ID: 24657719
[TBL] [Abstract][Full Text] [Related]
15. Preparation and preclinical evaluation of experimental group B streptococcus type III polysaccharide-cholera toxin B subunit conjugate vaccine for intranasal immunization.
Shen X; Lagergård T; Yang Y; Lindblad M; Fredriksson M; Holmgren J
Vaccine; 2000 Nov; 19(7-8):850-61. PubMed ID: 11115709
[TBL] [Abstract][Full Text] [Related]
16. Effect of conjugation methodology, carrier protein, and adjuvants on the immune response to Staphylococcus aureus capsular polysaccharides.
Fattom A; Li X; Cho YH; Burns A; Hawwari A; Shepherd SE; Coughlin R; Winston S; Naso R
Vaccine; 1995 Oct; 13(14):1288-93. PubMed ID: 8585282
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of synthetic schemes to prepare immunogenic conjugates of Vibrio cholerae O139 capsular polysaccharide with chicken serum albumin.
Kossaczka Z; Szu SC
Glycoconj J; 2000 Jun; 17(6):425-33. PubMed ID: 11294508
[TBL] [Abstract][Full Text] [Related]
18. Experience with Salmonella typhi Vi capsular polysaccharide vaccine.
Hessel L; Debois H; Fletcher M; Dumas R
Eur J Clin Microbiol Infect Dis; 1999 Sep; 18(9):609-20. PubMed ID: 10534182
[TBL] [Abstract][Full Text] [Related]
19. Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines.
Konadu E; Robbins JB; Shiloach J; Bryla DA; Szu SC
Infect Immun; 1994 Nov; 62(11):5048-54. PubMed ID: 7927787
[TBL] [Abstract][Full Text] [Related]
20. Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes.
Gupta RK; Egan W; Bryla DA; Robbins JB; Szu SC
Infect Immun; 1995 Aug; 63(8):2805-10. PubMed ID: 7542631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
